Company record
Beckman Coulter Ireland, Inc.
0 FDA warning letters since 2023 and 2 recalls in the last 12 months.
Get an email the day FDA posts anything new about Beckman Coulter Ireland, Inc..
Recalls
| Reported | Class | Firm | Product and reason |
|---|---|---|---|
| Jan 28 | Class II | Beckman Coulter Ireland, Inc. Device |
The LDL-Cholesterol assay is comprised of two distinct phases. In phase one a unique detergent solubilizes cholesterol from non-LDL- lipoprotein particles. This cholesterol is consumed by cholesterol esterase, cholestero… Beckman Coulter identified that LDL Cholesterol OSR6x96 is not meeting the performance claim listed in the Instructions for Use (IFU). LDL Cholesterol reagent showed clinically significant interference due to triglyceride concentration up to 1500 mg/dL may cause a maximum positive bias of up to 28.8% in low LDL Cholesterol samples (concentration 80 mg/dL) and up to 11.02% in high LDL Cholesterol samples (concentration 160mg/dL). FDA notice Z-1135-2026 |
| Dec 31, 2025 | Class II | Beckman Coulter Ireland, Inc. Device |
BECKMAN COULTER BICARBONATE REF: OSR6137 OSR6237 OSR6637 OSR6x37 Bicarbonate is a system reagent for the quantitative determination of Bicarbonate in human serum and plasma on Beckman Coulter AU analyzers. Bicarbonate reagent may generate falsely high Bicarbonate results due to interference with Lactate Dehydrogenase (LDH) in the test sample. FDA notice Z-0997-2026 |